Van ECK Associates Corp Has $2.44 Million Stock Holdings in Repligen Corporation $RGEN

Van ECK Associates Corp boosted its position in Repligen Corporation (NASDAQ:RGEN) by 173.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,887 shares of the biotechnology company’s stock after acquiring an additional 11,354 shares during the quarter. Van ECK Associates Corp’s holdings in Repligen were worth $2,441,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. United Capital Financial Advisors LLC bought a new position in shares of Repligen in the second quarter worth about $380,756,000. Opti Capital Management LP bought a new position in Repligen in the 4th quarter valued at approximately $2,399,209,000. Maverick Capital Ltd. acquired a new stake in Repligen in the first quarter valued at approximately $178,946,000. Wasatch Advisors LP bought a new stake in shares of Repligen during the first quarter worth $146,513,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after buying an additional 1,091,683 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on RGEN. Wells Fargo & Company boosted their price objective on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Wolfe Research began coverage on Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Evercore reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th. Citigroup upgraded Repligen to a “buy” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 13th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $166.43.

Insider Buying and Selling at Repligen

In related news, CFO Jason Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.60% of the stock is owned by corporate insiders.

Repligen Trading Down 1.9%

NASDAQ RGEN opened at $169.61 on Friday. The company has a market cap of $9.57 billion, a price-to-earnings ratio of 232.34, a P/E/G ratio of 3.16 and a beta of 1.05. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $188.73. The business has a 50 day moving average price of $155.13 and a 200-day moving average price of $134.02. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. During the same quarter in the prior year, the company posted $0.26 earnings per share. The business’s revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities analysts expect that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.